Observation of clinical effects of edaravone and oxiracetam combined with Shuxuetong injection in the treatment of patients with cerebral hemorrhage
10.3760/cma.j.issn.1008-6706.2018.11.021
- VernacularTitle: 奥拉西坦、依达拉奉和疏血通联合治疗脑出血的临床疗效观察
- Author:
Huijie ZHOU
1
;
Yue LI
2
;
Xiaolei WANG
3
;
Yuehua XIN
3
;
Yujuan LIU
4
;
Lihua FENG
1
Author Information
1. Department of Neurology, the People's Hospital of Haiyang, Haiyang, Shandong 265100, China
2. Department of Chinese and English 146 Class, Queen Mary of Nanchang University, Nanchang, Jiangxi 330031, China
3. Department of Nosocomial Infection Management, the People's Hospital of Haiyang, Haiyang, Shandong 265100, China
4. Department of Nursing, the People's Hospital of Haiyang, Haiyang, Shandong 265100, China
- Publication Type:Journal Article
- Keywords:
Cerebral hemorrhage;
Oxiracetam;
Edaravone;
Shuxuetong
- From:
Chinese Journal of Primary Medicine and Pharmacy
2018;25(11):1439-1443
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the therapeutic effects of edaravone, oxiracetam combined with Shuxuetong on cerebral hematoma and improvement of neurological function in patients with cerebral hemorrhage.
Methods:A total of 96 patients with cerebral hemorrhage were randomly divided into observation group and control group by the random number table method, with 48 cases in each group.The observation group received intravenous drip of edaravone (4.0g added into 0.9% sodium chloride injection to 250mL, intravenous drip, 1 time/d), oxiracetam(30mg added into 0.9% sodium chloride injection to 100mL solution, 30min intravenous drip, 2 times/d), and Shuxuetong injection(4mL added into 0.9% sodium chloride injection to 250mL, intravenous drip, 1 time/d) on the basis of routine treatment, and the control group was treated with routine treatment for cerebral hemorrhage.The efficacy and safety in the two groups after treatment of 21 days were observed.
Results:After treatment, the neurological deficit score and cerebral hematoma volume of the two groups were improved(all P<0.05), but the improvements of the observation group was significantly better than those of the control group[(4.44±3.20)points vs.(10.53±2.86)points, (21.83±3.85)points vs.(26.71±3.49)points, (7.83±5.31)mL vs.(13.74±6.16)mL, t=9.818, 6.506, 5.035, all P<0.01]. The total effective rate of the observation group was higher than that of the control group(87.5% vs.52.1%, χ2=14.740, P<0.05). No drug-related adverse reactions occurred in two groups.
Conclusion:The application of oxiracetam and edaravone combined with Shuxuetong injection in patients with cerebral hemorrhage can effectively improve the brain edema and nerve defect, it has a positive significance to promote the patients' recovery after cerebral hemorrhage, and it is worthy of clinical application.
